Haemonetics Co. (NYSE:HAE) Director Pedro P. Granadillo sold 12,322 shares of the company’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $114.50, for a total value of $1,410,869.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Pedro P. Granadillo also recently made the following trade(s):
- On Monday, September 17th, Pedro P. Granadillo sold 30,824 shares of Haemonetics stock. The shares were sold at an average price of $111.83, for a total value of $3,447,047.92.
Shares of NYSE HAE traded down $3.47 during mid-day trading on Friday, hitting $111.61. 667,800 shares of the company traded hands, compared to its average volume of 461,515. Haemonetics Co. has a 1 year low of $53.74 and a 1 year high of $117.56. The company has a market cap of $5.95 billion, a price-to-earnings ratio of 59.68, a P/E/G ratio of 3.67 and a beta of 1.09. The company has a quick ratio of 1.94, a current ratio of 2.92 and a debt-to-equity ratio of 0.47.
Hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Asset Management Inc purchased a new stake in shares of Haemonetics during the third quarter valued at $219,000. Wagner Bowman Management Corp purchased a new stake in shares of Haemonetics during the second quarter valued at $224,000. Arjuna Capital purchased a new stake in shares of Haemonetics during the second quarter valued at $224,000. Granahan Investment Management Inc. MA purchased a new stake in shares of Haemonetics during the second quarter valued at $229,000. Finally, Welch & Forbes LLC purchased a new stake in shares of Haemonetics during the third quarter valued at $229,000. 96.44% of the stock is owned by institutional investors and hedge funds.
HAE has been the subject of several research analyst reports. TheStreet lowered Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. Barrington Research restated a “buy” rating and issued a $127.00 price objective on shares of Haemonetics in a report on Friday, October 5th. Morgan Stanley upped their price objective on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, August 8th. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 7th. Finally, Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price objective for the company in a report on Friday, October 12th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $113.20.
COPYRIGHT VIOLATION WARNING: “Haemonetics Co. (HAE) Director Pedro P. Granadillo Sells 12,322 Shares” was originally published by Week Herald and is owned by of Week Herald. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://weekherald.com/2018/11/10/haemonetics-co-hae-director-pedro-p-granadillo-sells-12322-shares.html.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Article: Why do companies issue stock splits?
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.